ONCAlert | Upfront Therapy for mRCC
Biosimilars MORE >>
Pegfilgrastim-cbqv (CHS-1701; Udencya), a pegfilgrastim (Neulasta) biosimilar, has been granted approval by the FDA for patients with cancer receiving myelosuppressive chemotherapy.
Latest JournalAll Journals >>
Evolving Paradigms Non-Small Cell Lung Cancer
MORE >>